|
Mechanismadrenergic receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Australia |
First Approval Date03 Mar 2017 |
|
MechanismP2Y12 receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date27 Jul 2009 |
100 Clinical Results associated with Southern Cross Pharma Pty Ltd.
0 Patents (Medical) associated with Southern Cross Pharma Pty Ltd.
100 Deals associated with Southern Cross Pharma Pty Ltd.
100 Translational Medicine associated with Southern Cross Pharma Pty Ltd.